olanzapine-RAIM + placebo

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Schizophrenia

Conditions

Schizophrenia

Trial Timeline

Apr 1, 2006 → May 1, 2007

About olanzapine-RAIM + placebo

olanzapine-RAIM + placebo is a phase 2 stage product being developed by Eli Lilly for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00316238. Target conditions include Schizophrenia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00316238Phase 2Completed

Competing Products

20 competing products in Schizophrenia

See all competitors
ProductCompanyStageHype Score
antipsychotic dose increaseEli LillyPre-clinical
23
Olanzapine + PlaceboEli LillyPhase 3
77
Olanzapine + AripiprazoleEli LillyApproved
85
olanzapine therapyEli LillyApproved
85
Clozapine + OlanzapineEli LillyApproved
85
AtomoxetineEli LillyApproved
85
Risperidone + Placebo + LY2140023Eli LillyPhase 2
52
Olanzapine + olanzapine + risperidoneEli LillyApproved
85
Zotepine + RisperidoneAstellas PharmaApproved
85
ASP4345 + Matching PlaceboAstellas PharmaPhase 1
33
ASP4345 + placebo + risperidone + quetiapine + olanzapine + ziprasidone + aripiprazole + brexpiprazole + paliperidone + lurasidoneAstellas PharmaPhase 2
52
ASP6981 + PlaceboAstellas PharmaPhase 1
33
SAPHRIS + AsenapineSun PharmaceuticalPhase 1
33
Torrent's Quetiapine Fumarate TabletsTorrent PharmaceuticalsPhase 1
33
Olanzapine HydrochlorideEli LillyPhase 1/2
41
Rapid-Acting Intramuscular Olanzapine + PlaceboEli LillyPhase 3
77
Pomaglumetad methionilEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
Intramuscular Olanzapine Depot + PlaceboEli LillyPhase 3
77
olanzapine + atomoxetine + placeboEli LillyPhase 1/2
41